EICHORCondition: Schizophrenia · Sponsor: Vanda Pharmaceuticals
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * DSM-IV diagnosis of schizophrenia * PANSS-T of at least 70 at screening and baseline Exclusion Criteria: * Clinically significant disease of the heart, kidneys, liver or gastrointestinal system * DSM-IV diagnosis of psychiatric disorder other than schizophrenia
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Vanda Investigational Site | Little Rock, Arkansas, United States | — |
| Vanda Investigational Site | Anaheim, California, United States | — |
| Vanda Investigational Site | Cerritos, California, United States | — |
| Vanda Investigational Site | Garden Grove, California, United States | — |
| Vanda Investigational Site | Glendale, California, United States | — |
| Vanda Investigational Site | Los Angeles, California, United States | — |
| Vanda Investigational Site | National City, California, United States | — |
| Vanda Investigational Site | Oceanside, California, United States | — |
| Vanda Investigational Site | Paramount, California, United States | — |
| Vanda Investigational Site | Pico Rivera, California, United States | — |
| Vanda Investigational Site | San Diego, California, United States | — |
| Vanda Investigational Site | San Diego, California, United States | — |
+ 30 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00254202